CONFERENCES

Japanese Medical Society of Alcohol and Addiction Studies

JMSAAS is an annual conference that focuses on alcohol and addiction studies in Japan, with topics ranging from prevention strategies to treatment modalities, harm reduction, and rehabilitation. The conference is aimed at researchers, clinicians, educators, and policymakers, and provides a forum for sharing knowledge and collaborating on the latest scientific findings and emerging trends in alcohol and addiction studies. 

JMSAAS 2024

Content type

Conference

Date

Sep 19, 2024 - Sep 21, 2024

Location

Tokyo, Japan

Conference website

Conference description

The Japanese Alcohol, Nicotine & Drug Addiction Conference 2024 is themed “Creation of Addiction Treatment and Creation of Addiction Studies: Connecting Ideas and Challenging the Future” and focuses on advancing addiction research and treatment. 

JMSAAS 2022

Content type

Conference

Date

Sep 08, 2022 - Sep 10, 2022

Location

Sendai, Japan

Conference description

The theme of this meeting is "Alcohol Addiction Medicine and Science Required Today". 

JMSAAS 2016

Content type

Conference

Date

Oct 08, 2016

Location

Tokyo, Japan

Conference description

The 51th Annual Academic Meeting of JMSAAS : Addiction Science at the Viewpoint of Harm Reduction.

See related presentations

PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
​
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.